omaveloxolone (Skyclarys)

Indications

• treatment of Friedrich's ataxia in adults & adolescents >= 16 years

Contraindications

• avoid in patients with severe hepatic impairment
• pregnancy: may cause fetal harm

Dosage

• 150 mg (3 capsules) PO QD on empty stomach >= 1 hour prior to eating
  • swallow capsules hole, do not crush or chew
• 100 mg PO QD for moderate hepatic impairment
  • reduce dose to 50 mg PO QDif adverse effects emerge

* see Laboratory:

Adverse effects

• >= 20%
  • elevated serum ALT, serum AST
  • headache, abdominal pain, musculoskeletal pain
  • nausea, diarrhea
  • fatigue

Drug interactions

• moderate-strong CYP3A4 inhibitors
• moderate-strong CYP3A4 inducers

Laboratory

• obtain liver function tests, serum BNP & lipid panel prior to initiation & during treatment with omaveloxolone

Mechanism of action

• unknown
• activate Nrf2 pathway involved in response to oxidative stress

More general terms

• neurologic agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71811910
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=89884437